tradingkey.logo
tradingkey.logo
Search

ANI Pharmaceuticals Inc

ANIP
Add to Watchlist
78.010USD
-1.570-1.97%
Close 05/15, 16:00ETQuotes delayed by 15 min
1.75BMarket Cap
18.96P/E TTM

ANI Pharmaceuticals Inc

78.010
-1.570-1.97%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.97%

5 Days

-4.70%

1 Month

-0.08%

6 Months

-7.15%

Year to Date

-1.18%

1 Year

+30.04%

Key Insights

ANI Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 109.14.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ANI Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
14 / 155
Overall Ranking
52 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

ANI Pharmaceuticals Inc Highlights

StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 81.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 883.37M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 18.96, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 23.15M shares, increasing 0.25% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 74.78K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
109.143
Target Price
+34.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ANI Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ANI Pharmaceuticals Inc Info

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
Websitehttps://www.anipharmaceuticals.com/
KeyAI